Dopamine News and Research

RSS

Dopamine is a hormone and neurotransmitter occurring in a wide variety of animals, including both vertebrates and invertebrates. In the brain, this phenethylamine functions as a neurotransmitter, activating the five types of dopamine receptors — D1, D2, D3, D4 and D5, and their variants. Dopamine is produced in several areas of the brain, including the substantia nigra and the ventral tegmental area. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. Dopamine has many functions in the brain, including important roles in behavior and cognition, motor activity, motivation and reward, inhibition of prolactin production (involved in lactation), sleep, mood, attention, and learning. Dopaminergic neurons (i.e., neurons whose primary neurotransmitter is dopamine) are present chiefly in the ventral tegmental area (VTA) of the midbrain, substantia nigra pars compacta, and arcuate nucleus of the hypothalamus.

Researchers re-programme other cells to become nerve cells, directly in the brain

The field of cell therapy, which aims to form new cells in the body in order to cure disease, has taken another important step in the development towards new treatments.

26 Mar 2013

Study shows why certain drugs that interact with serotonin receptors have harmful effects

A team including scientists from The Scripps Research Institute (TSRI), the University of North Carolina at Chapel Hill and the Chinese Academy of Sciences has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor.

25 Mar 2013

Parkinson's Disease drug can help reverse age-related impairments in decision making: Study

A drug widely used to treat Parkinson's Disease can help to reverse age-related impairments in decision making in some older people, a study from researchers at the Wellcome Trust Centre for Neuroimaging has shown.

25 Mar 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Antipsychotic drugs associated with increased risk of stroke in the elderly

Antipsychotic administration in the elderly is associated with an increased risk for cerebrovascular accident, more commonly known as stroke; a new study published in Biological Psychiatry provides additional insight into this important relationship.

12 Mar 2013

Researchers develop new approach to screening potential treatments for Alzheimer's disease

According to a 2012 World Health Organization report, over 35 million people worldwide currently have dementia, a number that is expected to double by 2030 (66 million) and triple by 2050 (115 million).

11 Mar 2013

Scientists pinpoint neural basis for stress-related relapse in rat models

All too often, stress turns addiction recovery into relapse, but years of basic brain research have provided scientists with insight that might allow them develop a medicine to help. A new study in the journal Neuron pinpoints the neural basis for stress-related relapse in rat models to an unprecedented degree.

7 Mar 2013

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

Researchers at Columbia University Medical Center (CUMC), with collaborators at the Albert Einstein College of Medicine of Yeshiva University, have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells.

6 Mar 2013

New NIH collaborative initiative aims to accelerate search for biomarkers in Parkinson's

Last month, the National Institutes of Health announced a new collaborative initiative that aims to accelerate the search for biomarkers -- changes in the body that can be used to predict, diagnose or monitor a disease -- in Parkinson's disease, in part by improving collaboration among researchers and helping patients get involved in clinical studies.

6 Mar 2013

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

4 Mar 2013

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells.

4 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

Junk food during pregnancy changes development of opioid signaling pathway in the baby's brain

Here's another reason why a healthy diet during pregnancy is critical to the future health of your children: New research published in the March 2013 issue of The FASEB Journal, suggests that pregnant mothers who consume junk food actually cause changes in the development of the opioid signaling pathway in the brains of their unborn children.

1 Mar 2013

NINDS to award TSRI scientist with $3.5M Jacob K. Javits Neuroscience Investigator Award

Ron Davis, PhD, chair of the Neuroscience Department on the Florida campus of The Scripps Research Institute, has been selected to receive a prestigious $3.5 million Jacob K. Javits Neuroscience Investigator Award for his work on the complex biology of memory formation and the disorders that disrupt it.

21 Feb 2013

Study determines frequency of genetic variants linked to alcoholism for Spanish population

Research done at the UPV/EHU-University of the Basque Country has determined the frequency of genetic variants linked to alcoholism for the Spanish population, and its incidence not only in individuals with a high level of alcohol intake, but also in individuals with alcohol dependence.

20 Feb 2013

Study establishes possible link between high-fat diets and ADHD, learning disabilities

A University of Illinois study has established a possible link between high-fat diets and such childhood brain-based conditions as attention deficit hyperactivity disorder (ADHD) and memory-dependent learning disabilities.

19 Feb 2013

Parkinson's-related mutations may also affect vision

The most common genetic cause of Parkinson's is not only responsible for the condition's distinctive movement problems but may also affect vision, according to new research by scientists at the University of York.

16 Feb 2013

Stress and mental illness: an interview with Professor Akira Sawa

As a psychiatrist I am interested in how stress may play a role in the pathology of adult mental disorders. You may know that most of the major mental illnesses, such as schizophrenia, mood-disorder, substance abuse or even anxiety disorder, become prominent in early adulthood.

14 Feb 2013

Overexpression of alpha-synuclein can cause Parkinson's

Researchers at the University of California, San Diego School of Medicine say overexpression of a protein called alpha-synuclein appears to disrupt vital recycling processes in neurons, starting with the terminal extensions of neurons and working its way back to the cells' center, with the potential consequence of progressive degeneration and eventual cell death.

10 Feb 2013

Drugs that target retromer pathway could help prevent or treat Parkinson's

Columbia University Medical Center (CUMC) researchers have identified a protein trafficking defect within brain cells that may underlie common non-familial forms of Parkinson's disease.

9 Feb 2013

Dopamine News and Research

Further Reading

Researchers re-programme other cells to become nerve cells, directly in the brain

Study shows why certain drugs that interact with serotonin receptors have harmful effects

Parkinson's Disease drug can help reverse age-related impairments in decision making: Study

Promising studies for Parkinson's to be presented at 65th AAN meeting

Antipsychotic drugs associated with increased risk of stroke in the elderly

Researchers develop new approach to screening potential treatments for Alzheimer's disease

Scientists pinpoint neural basis for stress-related relapse in rat models

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

New NIH collaborative initiative aims to accelerate search for biomarkers in Parkinson's

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Junk food during pregnancy changes development of opioid signaling pathway in the baby's brain

NINDS to award TSRI scientist with $3.5M Jacob K. Javits Neuroscience Investigator Award

Study determines frequency of genetic variants linked to alcoholism for Spanish population

Study establishes possible link between high-fat diets and ADHD, learning disabilities

Parkinson's-related mutations may also affect vision

Stress and mental illness: an interview with Professor Akira Sawa

Overexpression of alpha-synuclein can cause Parkinson's

Drugs that target retromer pathway could help prevent or treat Parkinson's

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News